A Phase I, Open Label, Non-Randomized, Parallel Group, Pharmacokinetic Study in Subjects With Normal Renal Function, Moderate or Severe Renal Impairment Receiving a Single Dose of Oral 150 mg AZD3355.

Trial Profile

A Phase I, Open Label, Non-Randomized, Parallel Group, Pharmacokinetic Study in Subjects With Normal Renal Function, Moderate or Severe Renal Impairment Receiving a Single Dose of Oral 150 mg AZD3355.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2011

At a glance

  • Drugs Lesogaberan (Primary)
  • Indications Renal impairment
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 May 2010 Actual patient number (23) added as reported by ClinicalTrials.gov.
    • 05 May 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 05 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top